BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 10,182,590 | $495,281,183 | +1% | 3.63% |
| 2. | Orbis Investment Management William B. Gray | 2,764,532 | $134,466,837 | +77% | 0.65% |
| 3. | EcoR1 Capital Oleg Nodelman | 1,389,276 | $67,574,385 | 4% | |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,344,700 | $65,406,208 | +69% | 0.13% |
| 5. | SR One Capital Simeon George | 1,048,951 | $51,020,977 | 11.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $57.03 | 20,000 | $1,140,600.00 | 22,000 | 2025-08-06 | Filing | |
| $52.03 | 960,983 | $49,999,945.49 | 1,730,179 | 2025-07-16 | Filing | |
| $52.03 | 22,319 | $1,161,257.57 | 238,897 | 2025-07-16 | Filing | |
| $52.03 | 6,510 | $338,715.30 | 69,687 | 2025-07-16 | Filing | |
| $44.85 | 7,000 | $313,947.90 | 7,000 | 2025-02-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $67.91 | 50,895 | $3,456,279.45 | 254,201 | 2025-10-17 | Filing | |
| $66.60 | 4,242 | $282,517.20 | 205,096 | 2025-10-14 | Filing | |
| $66.60 | 1,076 | $71,661.60 | 83,402 | 2025-10-14 | Filing | |
| $58.15 | 13,081 | $760,660.15 | 207,004 | 2025-08-18 | Filing | |
| $35.94 | 3,932 | $141,316.08 | 6,068 | 2025-05-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,163,675 | $140,227,777 | 0.08% | |
| 2. | 131,300 | $8,394,009 | 0.01% | |
| 3. | 101,769 | $6,769,674 | 0.48% | |
| 4. | 93,205 | $6,040,616 | 1.04% | |
| 5. | 84,016 | $5,933,223 | 0.01% |
News See All
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP) Stock
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C.
10 Unstoppable Stocks to Buy and Hold for the Next 5 Years
As per Ajay Rajadhyaksha, Global Chairman of Research at Barclays, the US job growth has slowed, and China’s economic data have demonstrated weakness.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now.
11 Best Emerging Technology Stocks to Buy Right Now
While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence began rewriting them.
CRISPR Therapeutics AG (CRSP)’s Casgevy Expands Global Adoption in 2025
CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering biotech company focused on gene-editing medicines using CRISPR/Cas9 technology.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
H.C. Wainwright Lifts CRISPR Therapeutics’ (CRSP) Price Target on CASGEVy Sales Growth
CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood's Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C.
Cathie Wood Stock Portfolio: Top 10 Stocks to Buy Now
Cathie Wood, the CEO and chief investment officer of ARK Investment Management, has established a reputation thanks to high-conviction bets that often yield significant returns.
Hedge Fund Resource Center Billionaire Hedge Funds
